Higher Baseline Mucosal Inflammation Associated with Inferior UC Outcomes

A team of researchers from China conducted the study and published their findings in Clinics and Research in Hepatology and Gastroenterology. They explained that their goal was to determine a “fixed inflammatory-response score in ulcerative colitis biologic studies.”

Using “platform-specific probe mapping and accession-level baseline standardization,” the study authors calculated a “fixed 200-gene score.” In addition, the study team used three randomized datasets, including “active-versus-placebo” data to estimate “treatment-by-score interactions.”

To analyze the prognostic associations of baseline mucosal inflammation, the investigators used data from 7 pre-treated patient cohorts, while they determined longitudinal change and cellular localization using information from 6 paired cohorts and “donor-aware single-cell summaries,” respectively.

The investigators reported that the “randomized branch” of the study included 681 patients. They reported odds ratios for the treatment-by-score interactions from the 3 randomized datasets of 0.64, 0.46, and 0.76. However, the 95% confidence intervals (CI) of the datasets “were wide and crossed one.”

Out of 681 total participants, 541 individuals were receiving active treatment, and among those patients, higher baseline mucosal inflammation scores “were associated with poorer outcome (pooled odds ratio 0.44, 0.33-0.58).”

In contrast, among the 154 patients in the six paired cohorts, respondents showed a lower follow-up score after adjusting for baseline mucosal inflammation (-1.07 standardized units, -1.61 to -0.53).

“Analysis of 212,623 cells localized the programme across epithelial, myeloid, and fibroblast/pericyte compartments,” the study authors wrote. “Baseline compartment analyses included only 18-19 donors and did not establish a remission association.”

The investigators reflected on the findings and highlighted that baseline mucosal inflammation in patients with UC was consistently shown to correlate with inferior clinical outcomes, as well as a “response-associated decline” in patients across the evaluated datasets, although “treatment-effect modification” was not established by the study evidence.

“All three randomized interaction estimates were below one, but imprecise, so treatment-effect modification and treatment-selection utility were not established,” they explained. “Prospective independent validation is required before clinical use.”